Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Company Overview

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors. By combining gene-editing technologies with optimized cell expansion processes, the company aims to enhance tumor targeting, persistence and safety profiles. Its platform supports rapid manufacturing and scalable production, potentially enabling broader patient access and faster clinical development timelines.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Artiva Biotherapeutics operates in key biopharma hubs across North America and Europe. The company’s management team brings collective expertise in immuno-oncology, cell therapy manufacturing and clinical development, positioning Artiva to advance its candidate programs through pivotal trials and, ultimately, regulatory approval.

Key Stats

• Today's Range: $2.32 to $2.62
• 50-Day Range: $1.69 to $3.61
• 52-Week Range: $1.47 to $17.31
• Volume: 100,475 shs
• Average Volume: 70,270 shs
• Market Capitalization: $57.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Buy

Artiva Biotherapeutics Stock Analysis - MarketRank™

Artiva Biotherapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 417th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Artiva Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Artiva Biotherapeutics has a consensus price target of $17.00, representing about 623.4% upside from its current price of $2.35.

Amount of Analyst Coverage

Artiva Biotherapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($4.95) to ($2.83) per share.

Price to Book Value per Share Ratio

Artiva Biotherapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.45% of the float of Artiva Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Artiva Biotherapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artiva Biotherapeutics does not currently pay a dividend.

Dividend Growth

Artiva Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.45% of the float of Artiva Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Artiva Biotherapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Artiva Biotherapeutics has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Artiva Biotherapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Artiva Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $69,615.00 in company stock.

Percentage Held by Insiders

21.40% of the stock of Artiva Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

ARTV Stock Analysis - Frequently Asked Questions

How have ARTV shares performed this year?

Artiva Biotherapeutics' stock was trading at $10.08 at the beginning of the year. Since then, ARTV shares have decreased by 76.7% and is now trading at $2.35.

How were Artiva Biotherapeutics' earnings last quarter?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced its earnings results on Wednesday, August, 6th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.03.

When did Artiva Biotherapeutics IPO?

Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering (IPO) on Friday, July 19th 2024. The company issued 13,920,000 shares at a price of $12.00 per share.

Who are Artiva Biotherapeutics' major shareholders?

Artiva Biotherapeutics' top institutional shareholders include Geode Capital Management LLC (0.65%), Marshall Wace LLP (0.21%), Jane Street Group LLC (0.18%) and Qube Research & Technologies Ltd (0.16%). Insiders that own company stock include Yong-Jun Huh, Global Strategic Fund I Venbio and Fred Aslan.
View institutional ownership trends.

How do I buy shares of Artiva Biotherapeutics?

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Artiva Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARTV
• Previous Symbol: NASDAQ:ARTV
• CIK: 1817241
• Web: www.artivabio.com
• Phone: (858) 267-4467
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Artiva Biotherapeutics: $17.00
• High Price Target: $20.00
• Low Price Target: $12.00
• Potential Upside/Downside: +623.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.37 million
• Net Margins: N/A
• Pretax Margin: -26,045.02%
• Return on Equity: -42.60%
• Return on Assets: -37.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.84
• Quick Ratio: 13.84

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 229.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.68 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 24,430,000
• Free Float: 19,199,000
• Market Cap: $57.41 million
• Optionable: N/A
• Beta: 2.99